Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | EGFR | P00533 | 2/20 | 0.35 |
| ▸ | PIM3 | Q86V86 | 2/20 | 0.32 |
| ▸ | PIM1 | P11309 | 1/20 | 0.31 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.31 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16937932 | 0.78 | HTR2A (0.49) | MAPTEGFR | |
| SCHEMBL917628 | 0.77 | PRKCI (0.41) | HTR6MAPT | |
| SCHEMBL29958009 | 0.77 | HTR2C (0.50) | MAPT | |
| SCHEMBL12544395 | 0.77 | HTR2C (0.50) | MAPT | |
| SCHEMBL12127749 | 0.75 | APP (0.43) | EGFR | |
| SCHEMBL15024920 | 0.73 | HTR6 (0.46) | HTR6 | |
| SCHEMBL29236 | 0.72 | SLC6A2 (0.41) | — | |
| SCHEMBL3427242 | 0.72 | CYP2A6 (0.50) | HTR6MAPTEGFR | |
| SCHEMBL30720057 | 0.72 | CYP2A6 (0.50) | HTR6MAPTEGFR | |
| SCHEMBL28678513 | 0.71 | HTR2C (0.49) | HTR6MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110009428-A1 | NOVEL ANDROGENS | N.V. ORGANON (NL) | 2011-01-13 | — | — | US | disclosed |
| US-20110009428-A1 | NOVEL ANDROGENS | N.V. ORGANON (NL) | 2011-01-13 | — | — | US | disclosed |
| US-7812036-B2 | Androgens | N.V. ORGANON (NL) | 2010-10-12 | — | — | US | disclosed |
| EP-1742912-B1 | NOVEL ANDROGENS | ORGANON NV (NL) | 2010-08-25 | — | — | EP | disclosed |
| US-20070225352-A1 | Novel Androgens | PHARMACOPELA DRUG DISCOVERY, INC. (US) | 2007-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225352-A1 | Novel Androgens | NR5A1, AR, SHBG | HTR6 734/4885MAPT 1573/4885EGFR 1442/4885 |
| US-20110009428-A1 | NOVEL ANDROGENS | NR5A1, AR, NR3C2 | HTR6 209/4885MAPT 4558/4885EGFR 507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.